A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.

Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.

LIVE Educational Case...

An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).

One Pascal ACE device was implanted.

LIVE Educational Case from Nagoya...

This session presents pivotal late-breaking trials from PCR Tokyo Valves 2026, offering one-year outcomes and real-world experiences in transcatheter valve therapies. Highlights include the AltaValve early feasibility study on atrial fixation TMVR, invasive registry insights on prosthesis-patient mismatch post-TAVR, and registry data on tricuspid and mitral...

Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...

Dedicated to procedural imaging for tricuspid valve interventions, this session elucidates anatomical and pathophysiological features critical for successful transcatheter procedures. It emphasizes technical aspects of TEE and ICE imaging, including 3D multiplanar reconstruction, and offers case-based learning to refine imaging skills and optimize procedural outcomes.

This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...

The Welcome Ceremony marks the commencement of the conference, setting the stage for an engaging and informative program dedicated to advances in cardiology and interventional techniques. It provides attendees with an overview of the event's objectives and highlights the collaborative spirit of the cardiology community.

• Optimisation of side branch stenting
• How to optimally deploy the second stent

Commented by Goran Stankovic and William Wijns

Part 3 of a 3-part series. Previous episode: How to correct incomplete crush and how to prevent lack of carina coverage

Latest Stents, scaffolds and DCB content in interventional cardiology - research, practice, and education

Since 1986, when the first cardiovascular stent was implanted, the development of drug-eluting stents (DES) and the recent introduction of bioresorbable scaffolds have revolutionised interventional cardiology. Keep up-to-date with the latest research; evolving tools,...

Alex Sticchi provides his take on the TRILUMINATE pivotal trial which was presented by David H. Adams at the TCT Congress 2022.

A record 12,100 participants from 130 countries have just taken part in the highly educational WorldLeading Course in interventional cardiovascular medicine. They enjoyed a unique opportunity to exchange their knowledge, skills and experience on a global scale.

Paris – France, 17 May 2024. As always, the thought-provoking...

Michele Pighi provides his take on this trial which aimed to compare the safety and efficacy of VIV-TAVI with or without bioprosthetic valve fracture. It was presented by Santiago Garcia during the TCT Congress 2022.

EuroPCR, the annual world-leading Course in interventional cardiovascular medicine, has been taking place for over 30 years. It is tailored for all those dedicated to the sharing of knowledge and skills, and improvement of patient care worldwide: interventional cardiologists, cardiac surgeons, imaging specialists, radiologists, nurses, allied...

Charles Fauvel provides his take on the RELIEVE-HF study outcomes presented by Gregg W. Stone at ACC.24 in Atlanta.

Jonathan Curio and Alex Sticchi provide their take on this clinical trial which was presented by Paul Sorajja at the American College of Cardiology Scientific Session (ACC.23/WCC).

Elad Asher provides his take on the primary biomarker analysis from the EARLY TAVR Trial presented by Brian R. Lindman at ACC.25 in Chicago.

Kalaivani Mahadevan and Sofia Papadopoulou provide their take on the INVEST CTO trial, presented by Anja Oksnes at TCT 2025, in San Francisco.

Make the most of the insights from Jacob Thomsen Loenborg’s interview with Chiara De Biase and Ali Nazmi Calik’s article to capture the key takeaways from this trial, simultaneously published in the NEJM, presented at the ESC Congress 2024 in London.